APPENDIX 24 – ECONOMIC EVIDENCE PROFILE

Clinical / economic question: pharmacological and psychological interventions for adults with social anxiety

Study & country	Limitations	Applicability	Incremental cost versus waitlist (£)[1]	Incremental QALYs versus waitlist	Net monetary benefit	Uncertainty
Guideline economic analysis, UK	Minor limitations[2]	Directly applicable[3]	CT stand 1,388 CBT indiv 971 CBT Heim indiv 1,058 CT short 1,176 Phenelzine -87 Supported SH int 564 Exposure 723 Supported SH book 113 CBT group 744 Unsupported SH book 757 CBT Heim group 178 Venlafaxine 75 -54 Paroxetine 107 Venlafaxine 150 27 Fluvoxamine 1,678 Psych psychotherapy 84 Escitalopram -10 Mirtazapine -6 Fluoxetine 481 Unsupported SH in 276 Pregabalin 122 Moclobemide 24 Citalopram 42 Sertraline 1,216 IPT 371 Mindfulness 89 Placebo 1,194 Supportive therapy 0 Wait list	CT stand 0.382 CBT indiv 0.270 CBT Heim indiv 0.246 C&W short 0.216 Phenelzine 0.215 Supported SH int 0.178 Exposure 0.177 Supported SH book 0.177 CBT group 0.164 Unsupported SH book 0.162 CBT Heim group 0.156 Venlafaxine 75 0.145 Paroxetine 0.137 Venlafaxine 150 0.127 Fluvoxamine 0.120 Psych psychotherapy 0.111 Escitalopram 0.105 Mirtazapine 0.100 Fluoxetine 0.100 Unsupported SH in 0.095 Pregabalin 0.080 Moclobemide 0.079 Citalopram 0.076 Sertraline 0.072 IPT 0.071 Mindfulness 0.069 Placebo 0.030 Supportive therapy 0.027 Wait list 0.000	CT stand 69,495 CBT indiv 67,683 Phenelzine 67,640 CBT Heim indiv 67,112 Supported SH book 66,675 Unsupported SH 66,571 book 66,385 CT short 66,246 Supported SH in 66,127 Venlafaxine 75 66,070 Exposure 66,047 Paroxetine 65,787 CBT group 65,681 Venlafaxine 150 65,628 Fluvoxamine 65,617 CBT Heim group 65,267 Mirtazapine 65,265 Escitalopram 65,247 Fluoxetine 64,775 Citalopram 64,713 Moclobemide 64,670 Unsupported SH in 64,638 Sertraline 64,578 Pregabalin 64,258 Mindfulness 63,792 Psych psychotherapy 63,759 Placebo 63,457 IPT 63,248 Wait list 62,590 Supportive therapy	Probabilistic analysis: probability of CT stand having highest net monetary benefit 61% One-way deterministic analysis: results not sensitive to alternative unit costs and utility values

1. Costs uplifted to 2011 UK pounds using the UK HCHS inflation index.
2. Efficacy data taken from guideline NWMA; side effects of drugs (including disutilities and management costs) not considered; resource use based on published data and GDG expert opinion; national unit costs used; probabilistic and deterministic sensitivity analysis conducted
3. NHS & PSS perspective, QALYs based on EQ-5D UK tariff, annual discount rate 3.5%